Ishara Investments LP Makes New Investment in Biohaven Ltd. $BHVN

Ishara Investments LP bought a new position in shares of Biohaven Ltd. (NYSE:BHVN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 88,000 shares of the company’s stock, valued at approximately $994,000.

Several other large investors also recently bought and sold shares of BHVN. Infinitum Asset Management LLC grew its position in Biohaven by 267.6% during the 4th quarter. Infinitum Asset Management LLC now owns 6,250,000 shares of the company’s stock worth $70,562,000 after purchasing an additional 4,550,000 shares during the last quarter. Stifel Financial Corp lifted its stake in Biohaven by 50.3% during the 4th quarter. Stifel Financial Corp now owns 9,939,856 shares of the company’s stock valued at $112,221,000 after acquiring an additional 3,328,506 shares during the period. Schonfeld Strategic Advisors LLC lifted its stake in Biohaven by 3,829.9% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 1,606,777 shares of the company’s stock valued at $18,141,000 after acquiring an additional 1,565,891 shares during the period. Vanguard Group Inc. lifted its stake in Biohaven by 52.9% during the 4th quarter. Vanguard Group Inc. now owns 4,395,946 shares of the company’s stock valued at $49,630,000 after acquiring an additional 1,520,756 shares during the period. Finally, State Street Corp lifted its stake in Biohaven by 34.2% during the 4th quarter. State Street Corp now owns 5,716,487 shares of the company’s stock valued at $64,539,000 after acquiring an additional 1,458,204 shares during the period. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Biohaven Stock Performance

BHVN opened at $13.69 on Thursday. The company has a debt-to-equity ratio of 1.87, a current ratio of 7.41 and a quick ratio of 7.41. The firm has a fifty day moving average price of $10.18 and a 200 day moving average price of $10.57. Biohaven Ltd. has a 1 year low of $7.48 and a 1 year high of $18.57. The stock has a market cap of $2.06 billion, a P/E ratio of -2.41 and a beta of 1.35.

Biohaven (NYSE:BHVN) last posted its earnings results on Monday, May 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Equities research analysts anticipate that Biohaven Ltd. will post -3.07 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on BHVN shares. Raymond James Financial restated a “strong-buy” rating on shares of Biohaven in a research note on Wednesday, May 27th. TD Cowen lifted their price objective on shares of Biohaven from $15.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Citigroup lifted their price objective on shares of Biohaven from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. Royal Bank Of Canada decreased their price objective on shares of Biohaven from $23.00 to $22.00 and set an “outperform” rating for the company in a research note on Tuesday, May 5th. Finally, HC Wainwright restated a “neutral” rating and set a $10.00 price objective on shares of Biohaven in a research note on Tuesday, May 26th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $22.27.

Biohaven Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.